Inebilizumab
- Generic Name
- Inebilizumab
- Brand Names
- Uplizna 3 Vial Kit, Uplizna
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1299440-37-1
- Unique Ingredient Identifier
- 74T7185BMM
- Background
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface...
- Indication
Inebilizumab is indicated for the treatment of aquaporin-4 (AQP4) immunoglobulin-positive (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) in adult patients.
- Associated Conditions
- Neuromyelitis Optica Spectrum Disorders
- Associated Therapies
- -
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT04174677
- Locations
- 🇺🇸
Reserach Site California, San Diego, California, United States
🇺🇸Pennsylvania Reserach Site, Bethlehem, Pennsylvania, United States
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 231
- Registration Number
- NCT02200770
- Locations
- 🇹🇷
Research Site, Samsun, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.